A Phase 2 interventional study of SLx-2101 in Hypertension, sponsored by Retension Pharmaceuticals. Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Retension Pharmaceuticals. Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 223 studies in Hypertension with a site in United Kingdom — 35 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.
Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 150th largest by enrollment of the 172 interventional ones that give a count, is one of 5 that started in 2007, is one of 26 in phase 2, and was the 33rd registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →35 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:
CRISPR Therapeutics AG · Sites in United Kingdom, United States, Australia
Ages 18–75
King's College London · Sites in United Kingdom
Ages 10–25 · Healthy volunteers
Northumbria University · Sites in United Kingdom
Ages 18+
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18–40
Medtronic Vascular · Sites in United Kingdom, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 48 · Phase 4 20
First in 1997; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 125 across the 172 interventional studies, 200 across the 50 observational. Of the 156 that completed or were terminated, 52 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 223 have an industry lead sponsor. The 10 most frequent:
Retension Pharmaceuticals. Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Retension Pharmaceuticals. Inc. has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypertension with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 223 studies in Hypertension with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SLx-2101
Drug: SLx-2101
Matching Placebo Dose
Drug: SLx-2101
Office seated peripheral systolic and diastolic blood pressure
Time frame: 12 days
Adverse events and changes in vital signs
Time frame: 12 days
The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SLX-2101
Retension Pharmaceuticals. Inc.